<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Molecular Pathology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E78313EF-B2FD-4FE8-987E-F0E13BA6CB24"><gtr:id>E78313EF-B2FD-4FE8-987E-F0E13BA6CB24</gtr:id><gtr:firstName>Colin Stephen</gtr:firstName><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802851"><gtr:id>A15E5CE8-CAAB-48B8-9E8C-FA54F58E1F45</gtr:id><gtr:title>NCRI South of England Prostate Cancer Collaborative: Infrastructure Renewal</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802851</gtr:grantReference><gtr:abstractText>Following a review carried out on prostate cancer by the Cancer Research Funders Forum in 2000 major funding bodies including Cancer Research UK, the MRC and The Department of Health joined forces to injected new funds into prostate cancer research, in recognition that research on this common cancer was grossly under-funded. Two Prostate Cancer Research Collaboratives (PCCs) headed by Professor Colin Cooper and Professor David Neal were set up in 2001. The vision for the two PCCs has been to use these funds to (1) support competitive programmes of translational science to enable them to become self-sustaining; (2) to establish programmes for training young people in prostate cancer research; (3) to provide pump-priming funding for innovative projects; and (4) to provide infra-structure to develop a well-characterised bio-repository for prostate cancer research to support the science. As a result of this initiative the PCCs have created an internationally competitive prostate cancer community within the UK that did not exist prior to the setting up of the PCCs. This application is a request for two years of NCRI funding to support PCC infrastructure, including bio-repositories and databases, that underpins this initiative.</gtr:abstractText><gtr:technicalSummary>Both the Southern and ProMPT Prostate Cancer Collaboratives (PCCs) are dedicated to setting up internationally competitive research aimed at understanding the aetiology and subsequent mechanisms involved in prostate carcinogenesis, developing improved markers for predicting the clinical behaviour of prostate cancer, and discovering new treatment strategies. This has been achieved by recruiting new scientists and clinicians; re-orientating the interest of existing research groups; training new young scientists and clinicians; and building translational networks. In short we have created an internationally competitive prostate cancer community within the UK that did not exist prior to the setting up of the PCCs. Importantly the PCCs have now had a number of international successes. Critically all of these ongoing activities are dependent on NCRI funded infrastructure. The NCRI infrastructure requested in this application will continue to be used (i) for the collection of tissues for bio-repositories, (ii) to prepare biological specimens in a form (eg preparation of TMAs, DNA, and RNA) that is of more immediate use to scientists (iii) to construct a joint PCC databases to store information on biological samples their linked experimental results. In particular these activities underpin the joint PCC biomarker discovery and the joint NCRI Prostate Cancer Map Project.</gtr:technicalSummary><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>300699</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Molecular genetic analysis of prostate cancer</gtr:description><gtr:id>364F25BA-DB23-47C9-930C-AD1E9188181B</gtr:id><gtr:impact>Publications in Section 2.</gtr:impact><gtr:outcomeId>K6PtgtNCXaw-1</gtr:outcomeId><gtr:partnerContribution>Genetic analysis of prostate cancer patients.</gtr:partnerContribution><gtr:piContribution>Collaboration on expression profiling of human prostate, cancer, biomarker discovery and genetic analysis of prostate cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Pathology of prostate cancer</gtr:description><gtr:id>3A195011-CFDF-49E8-9008-41E8E90404F6</gtr:id><gtr:impact>publications in section 2</gtr:impact><gtr:outcomeId>pQh3TNwDCsh-1</gtr:outcomeId><gtr:partnerContribution>Carrying out histopathology of prostate cancers for biomarker discovery.</gtr:partnerContribution><gtr:piContribution>Collaboration on biomarker discovery</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Aetiology of prostate cancer</gtr:description><gtr:id>1D36E839-A092-43F9-BB0B-BDF6A395A830</gtr:id><gtr:impact>Many publications listed in section 2 (search Key T author)</gtr:impact><gtr:outcomeId>qFc5p7GTtrz-1</gtr:outcomeId><gtr:piContribution>This work has formed part of the NCRI prostate cancer collaborative</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Keele University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Life Sciences</gtr:department><gtr:description>Apoptosis in prostate cancer</gtr:description><gtr:id>A337E8F4-BD84-4345-9CA0-A4837D89CE84</gtr:id><gtr:impact>PMID 19023142</gtr:impact><gtr:outcomeId>ZSP7NibfmmW-1</gtr:outcomeId><gtr:partnerContribution>For a small investiment of infrastructure we were able to redirect the research interests of this group towards prostate cancer.</gtr:partnerContribution><gtr:piContribution>Provision of infrastructure to work on prostate cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Membership of patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>00C149A3-A633-4101-860F-3BECC36EBAB1</gtr:id><gtr:impact>Dr Parker is medical advisor to PCaSO Prostate Cancer Network, and has close links to the Prostate Cancer Support Federation, speaking at their launch meeting in 2007 and at 'The Great PSA debate' they hosted in 2009. has been a member of the Prostate Cancer Charter for Action Steering Group (2002-2005), and the Prostate Cancer Charity Research Strategy Review Committee. Recruitment to the Active Surveillance study has been facilitated by liaison with the Prostate Cancer Charity, the Prostate Cancer Support Organisation (PCaSO), and the PSA Prostate Cancer Support Association. Prof Dearnaley was an advisor to Prostate Cancer Research UK's &amp;quot;Ignorance isn't Bliss&amp;quot; Campaign. Prof Cooper and Prof Foster are on the scientific advisory boards of Tenovus and The Prostate Cancer Charity.

Education of protate cancer patients. Assisting in changing public policy.</gtr:impact><gtr:outcomeId>Y194xB4Vr18</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Running national prostate charity</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>91624232-0651-4F6E-B836-4933E503BD63</gtr:id><gtr:impact>Professor Cooper was involved in setting up a national prostate cancer charity called 'everyman' aimed at raising awareness of issue relating to prostate cancer

National awareness of under funding of prostate cancer research. Awareness of symptoms.</gtr:impact><gtr:outcomeId>bab3uMuKK79</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3B231DD3-90AE-4793-A61C-D9AA0C33F312</gtr:id><gtr:impact>Member of the Collaborative have given many public lectured. For example Paul Workman has given CRUK lectures including 'Drugging the Cancer Genome: Design of personalised cancer medicines' specifically highlighting drugs relevant to prostate cancer including PI3K and HSP90. His work has been highlighted as Editors choice in Drug Discovery Today (http://newsletter.drugdiscoverytoday.com/generated/default/f14/theview.htm)

Education of the public and health professionals.</gtr:impact><gtr:outcomeId>qchLdWFwGNi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://newsletter.drugdiscoverytoday.com/generated/default/f14/theview.htm</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Competitive Research Application</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>02C2F593-5991-4157-9BC3-7A2727D7322C</gtr:id><gtr:outcomeId>NRRRgeMrF1a0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>242263</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant/Bob Champion Cancer Trust</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Bob Champion Cancer Trust</gtr:fundingOrg><gtr:id>FE68F0BE-D3B9-49F0-A593-9870517EDEED</gtr:id><gtr:outcomeId>Sd1NW8zc69j0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Freemasons' Grand Charity Career Award (10 years)</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>The Freemasons' Grand Charity</gtr:fundingOrg><gtr:id>028C319D-1E76-4C42-A98E-2829DE8A3A3D</gtr:id><gtr:outcomeId>VoWnbBQAzBU0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>288000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCRI Infrastructure renewal</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>National Cancer Research Institute (NCRI)</gtr:fundingOrg><gtr:id>F7C1532B-8A76-4BCA-9AAF-0A0CB3BF3010</gtr:id><gtr:outcomeId>jhyxG4muxHH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant/The Prostate Cancer Charity</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>0EF4076C-3439-4C16-B46B-BCB70596E58F</gtr:id><gtr:outcomeId>MkqFt7zF9aV0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>152475</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Competitive Research Applications/The Prostate Cancer Charity UK</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>6654AFDC-6F23-43EC-BAC0-908E3006C90A</gtr:id><gtr:outcomeId>KJY7gRxGqaY0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148443</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>6AAB6CC8-9743-469F-BF81-39F3A3723A6F</gtr:id><gtr:outcomeId>bBaUyWfvhxJ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of The Prostate Cancer Advisory Group</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>4D3FF1A8-7C5F-40F4-98B9-8693ADA37157</gtr:id><gtr:impact>Input into desicion making</gtr:impact><gtr:outcomeId>R55GeeiWcvD</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9BF468C2-5A00-43BD-A7CB-637A67BFA94E</gtr:id><gtr:title>All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e517cfff04ef653a47b9e88de3a6e95"><gtr:id>9e517cfff04ef653a47b9e88de3a6e95</gtr:id><gtr:otherNames>Coumans FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>jVg1pgYtrG2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>765F1C6C-B545-46F9-B690-5E6F2A4FE591</gtr:id><gtr:title>Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f916785d45262e78b21f0f9e558423bf"><gtr:id>f916785d45262e78b21f0f9e558423bf</gtr:id><gtr:otherNames>Vergis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pyAA3jGqzh1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>178CAC65-B689-4032-828D-944A89C537EE</gtr:id><gtr:title>Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>kW4iM6qTpTi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F255A102-8F61-4CDB-8D8F-4F9DC2D99E6C</gtr:id><gtr:title>Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1855af15754b4ff0692fdd6ec7a5a94e"><gtr:id>1855af15754b4ff0692fdd6ec7a5a94e</gtr:id><gtr:otherNames>Gu F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>GECp7J6qDyV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E481FA22-9340-4371-B857-1D0307B3337A</gtr:id><gtr:title>Molecular origin of plasma membrane citrate transporter in human prostate epithelial cells.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3da9c5ddad5bb55b2a9d614d4802cc9"><gtr:id>c3da9c5ddad5bb55b2a9d614d4802cc9</gtr:id><gtr:otherNames>Mazurek MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>qoRPooLf3uX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>677CC284-9596-4A73-898B-CA1BFEFA4282</gtr:id><gtr:title>A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fd7a99ad803d87bb45f67651daa6a8f"><gtr:id>0fd7a99ad803d87bb45f67651daa6a8f</gtr:id><gtr:otherNames>Schumacher FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>FdbYjjzLcjQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2C71FFF-62A9-4480-8E1E-E25792DB8048</gtr:id><gtr:title>The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62730aefd0577078ade3de69fe3cf32"><gtr:id>b62730aefd0577078ade3de69fe3cf32</gtr:id><gtr:otherNames>Shan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>haBcREYZqAB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17B4F400-88DC-41EB-AAC6-04AE04F89BEB</gtr:id><gtr:title>The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aae9a52466dcebaa8fe2c657766fde73"><gtr:id>aae9a52466dcebaa8fe2c657766fde73</gtr:id><gtr:otherNames>Cook GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>L2YaMJoCDVn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C551726-64FD-4CF4-823C-600A64780094</gtr:id><gtr:title>Screening for prostate cancer: the way ahead.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9db502187a17ab91596ff676b72b9ec"><gtr:id>c9db502187a17ab91596ff676b72b9ec</gtr:id><gtr:otherNames>Kirby RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>KXgdanZvumz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B90E707-9C57-4341-AA29-F838F71349A8</gtr:id><gtr:title>Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/456242cd91bd5ac987e5dc063348b5ac"><gtr:id>456242cd91bd5ac987e5dc063348b5ac</gtr:id><gtr:otherNames>Battaglia S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>JDEwX74ZrUt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CA69405-8664-4DB3-8F25-A7CD2CEB5700</gtr:id><gtr:title>Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d9603b8918dceb92094532bf53a9826"><gtr:id>1d9603b8918dceb92094532bf53a9826</gtr:id><gtr:otherNames>Horwich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>U9kwKwAGg8o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F42E5ED-0BE4-495D-8C03-67064A8FA237</gtr:id><gtr:title>Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam).</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db36806f1e91eddb6f74a51dc65ebe5c"><gtr:id>db36806f1e91eddb6f74a51dc65ebe5c</gtr:id><gtr:otherNames>Kerkhof M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>WUrkE6g8h5e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C542280A-0969-4D3A-93E9-64FA711F81CB</gtr:id><gtr:title>Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42c9174e756a46da47186c614c7acfde"><gtr:id>42c9174e756a46da47186c614c7acfde</gtr:id><gtr:otherNames>Kynaston H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>DCNnWVbUEvg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>974031CB-8280-4A80-A346-021FB0420ABA</gtr:id><gtr:title>Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance.</gtr:title><gtr:parentPublicationTitle>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1010-4283</gtr:issn><gtr:outcomeId>ioShcuHwwB5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F00D314-8C84-40B5-B49F-A406C24E4A05</gtr:id><gtr:title>Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c5a2be51e66eaa478268ae98d8d4c5c"><gtr:id>6c5a2be51e66eaa478268ae98d8d4c5c</gtr:id><gtr:otherNames>Guerrero Urbano T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>rbBTS8Mn38R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CC5D43B-21EE-423A-B1F3-7598730FA630</gtr:id><gtr:title>Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb6185d79137a579b502858f48f0b280"><gtr:id>fb6185d79137a579b502858f48f0b280</gtr:id><gtr:otherNames>Reid AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>DkNM4fHcYh3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFBAEE90-0F80-4798-A76D-F0373E414F74</gtr:id><gtr:title>Steroid hormone receptors in prostate cancer: a hard habit to break?</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>PmQQACQTCGX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D06EB494-86F7-4E80-B3BC-A21CF8CAC4C4</gtr:id><gtr:title>Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.</gtr:title><gtr:parentPublicationTitle>Virchows Archiv : an international journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b345d54518ffc4a2481d465b2001e07b"><gtr:id>b345d54518ffc4a2481d465b2001e07b</gtr:id><gtr:otherNames>Rajab R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0945-6317</gtr:issn><gtr:outcomeId>i2SAs1zCPnP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CE40AC9-FD81-4284-927B-EF56E58C2E8A</gtr:id><gtr:title>Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>rzZUQb8Tdtt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>885EBDCA-B008-4669-95B3-CAD7F3E53078</gtr:id><gtr:title>Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.</gtr:title><gtr:parentPublicationTitle>Oncology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3736f6faf812d35be9b1eab7b2410f87"><gtr:id>3736f6faf812d35be9b1eab7b2410f87</gtr:id><gtr:otherNames>Mitra AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1021-335X</gtr:issn><gtr:outcomeId>WqoknjM8iBD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB58C5D8-B937-4027-B59C-83D661AC9BA2</gtr:id><gtr:title>Treating prostate cancer with radiotherapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33473d38823bd92ba28222ecf7473ef2"><gtr:id>33473d38823bd92ba28222ecf7473ef2</gtr:id><gtr:otherNames>Wilkins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>HztxDyQW1T9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEBA1F66-5438-4602-903A-B098B96F5206</gtr:id><gtr:title>Identification of EphrinB1 expression in prostatic mesenchyme and a role for EphB-EphrinB signalling in prostate development.</gtr:title><gtr:parentPublicationTitle>Differentiation; research in biological diversity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50905df355cf03a665509676abbe8f48"><gtr:id>50905df355cf03a665509676abbe8f48</gtr:id><gtr:otherNames>Ashley GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0301-4681</gtr:issn><gtr:outcomeId>Zcz8sXckmu5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4E4D547-4C59-4449-A116-AED9994E3E86</gtr:id><gtr:title>Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccece2fda072c09f5b16cc8331e40540"><gtr:id>ccece2fda072c09f5b16cc8331e40540</gtr:id><gtr:otherNames>McVey GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>etS4DzdStR9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969FEEA5-F04E-4DD6-A907-A8D7D5417994</gtr:id><gtr:title>SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce350f910b3fbceb089e8788fa4f4651"><gtr:id>ce350f910b3fbceb089e8788fa4f4651</gtr:id><gtr:otherNames>Thomsen MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>SbU5T8zE7F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AF61D7F-C998-4DC3-95AC-CBA80D3FBFF2</gtr:id><gtr:title>Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05f907f48788c8a9bbffca64f22046e0"><gtr:id>05f907f48788c8a9bbffca64f22046e0</gtr:id><gtr:otherNames>Christensen GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>AERF4DiRqha</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CFE2071-E055-4627-8858-65116B04C6F6</gtr:id><gtr:title>Adjuvant vs. salvage radiotherapy for pathologically advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccece2fda072c09f5b16cc8331e40540"><gtr:id>ccece2fda072c09f5b16cc8331e40540</gtr:id><gtr:otherNames>McVey GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>Zm7D5Uv6kPT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E196BD34-C063-45DF-92CF-DD3A034E7AB5</gtr:id><gtr:title>Apoptosis regulators Fau and Bcl-G are down-regulated in prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>Caz3kBX4hdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F49CBC63-843D-4131-8588-9F74A8D66E34</gtr:id><gtr:title>Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d147a316c0312db5abeb923d7d252ddd"><gtr:id>d147a316c0312db5abeb923d7d252ddd</gtr:id><gtr:otherNames>Martin FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>kWuY4PNvDbB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>548F2132-1EF7-4E62-BE3C-352E0BA28FE5</gtr:id><gtr:title>Information needs of early-stage prostate cancer patients: a comparison of nine countries.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb3427d26b5e20aa69a346edf28629a9"><gtr:id>cb3427d26b5e20aa69a346edf28629a9</gtr:id><gtr:otherNames>Feldman-Stewart D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>Frz41h5b3rL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90114BD6-E0A9-4BE6-BC0F-A4E0A462E36C</gtr:id><gtr:title>Using Bayesian logistic regression to evaluate a new type of dosimetric constraint for prostate radiotherapy treatment planning.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d0b20cc7b4a60cc062341333892bd7"><gtr:id>68d0b20cc7b4a60cc062341333892bd7</gtr:id><gtr:otherNames>Buettner F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>kqqnMpowaFv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59C3B056-09F7-453A-A9B2-D1E561024330</gtr:id><gtr:title>Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb6185d79137a579b502858f48f0b280"><gtr:id>fb6185d79137a579b502858f48f0b280</gtr:id><gtr:otherNames>Reid AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>kcNrWpQcF9a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B7772E-3DE1-4E4F-83A2-16BC1EDE5F38</gtr:id><gtr:title>Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ed4d8d10fe20acf976d0782bf483405"><gtr:id>6ed4d8d10fe20acf976d0782bf483405</gtr:id><gtr:otherNames>Danila DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>seJaENyWYQy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13E63124-6F1A-470E-AD36-D3F1FBA4602B</gtr:id><gtr:title>Dietary fat and early-onset prostate cancer risk.</gtr:title><gtr:parentPublicationTitle>The British journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d6f16b9db3bd1004c5f4ed5f865d8c0"><gtr:id>1d6f16b9db3bd1004c5f4ed5f865d8c0</gtr:id><gtr:otherNames>Lophatananon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1145</gtr:issn><gtr:outcomeId>oqg7hBMqbHm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CE3A07F-EDE8-4A0E-838C-1D1C7B5EE356</gtr:id><gtr:title>Prostate cancer diagnosis: should patients with prostate specific antigen &amp;gt;10ng/mL have stratified prostate biopsy protocols?</gtr:title><gtr:parentPublicationTitle>Cancer detection and prevention</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfb4011bd3f67d53915afe58f1cc3806"><gtr:id>dfb4011bd3f67d53915afe58f1cc3806</gtr:id><gtr:otherNames>Philip J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0361-090X</gtr:issn><gtr:outcomeId>fZxKgyVS8Vc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90F28D80-275C-4B00-A747-D5C7F9164A08</gtr:id><gtr:title>Mutation analysis of the MSMB gene in familial prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>hfH82jL58BG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C8F819B-9DEC-4ADF-BEC7-99B61B012649</gtr:id><gtr:title>Effects of a prostate awareness pilot on GP consultations and PSA requests.</gtr:title><gtr:parentPublicationTitle>Family practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/116576ae71b70349068564a6f9700df5"><gtr:id>116576ae71b70349068564a6f9700df5</gtr:id><gtr:otherNames>Melia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0263-2136</gtr:issn><gtr:outcomeId>AX2wvnAsFTR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD793157-1F24-49BC-B579-B042251927CE</gtr:id><gtr:title>Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/087f1ce750811bd48db7f48ded81f389"><gtr:id>087f1ce750811bd48db7f48ded81f389</gtr:id><gtr:otherNames>Edwards SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>tj5ghoRwt2o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A184D31-4B0C-4731-ADC3-2A323ED8C27C</gtr:id><gtr:title>Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a6beffb1b3dfaecfccd9f955cc3b231"><gtr:id>2a6beffb1b3dfaecfccd9f955cc3b231</gtr:id><gtr:otherNames>Price AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>qLBn6fDMnqL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>305174F5-06ED-4C20-B626-C45D37DF9BCD</gtr:id><gtr:title>Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2542f1fab010ad9c41ec254352692c1"><gtr:id>f2542f1fab010ad9c41ec254352692c1</gtr:id><gtr:otherNames>O'Brien MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>fp5CGG5uiYh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A29BF2B7-9864-4AC8-A7CD-3C08D4D700D2</gtr:id><gtr:title>Prostate radiotherapy after radical prostatectomy: sooner or later?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/142c3099ad7ed7c7b05389bf43f3732c"><gtr:id>142c3099ad7ed7c7b05389bf43f3732c</gtr:id><gtr:otherNames>Catton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>mWC8cBd1Euj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1493B26-99FB-49FF-8FC7-8D69B500E9D5</gtr:id><gtr:title>Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>QcEy2seBciH</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802851</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>